Literature DB >> 4202731

Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.

D T Fearon, K F Austen, S Ruddy.   

Abstract

The present studies demonstrate that the factor B-dependent C3 convertase can be affixed to an erythrocyte by use of an intermediate bearing C3b and that this convertase brings the hemolytic reaction to completion with an efficiency comparable to that of classical convertase. The evidence that the EAC43 intermediate was lysed by a new pathway includes requirements for factors B and D and cell-bound C3b for subsequent lysis by the terminal components, C3-C9. The linear stoichiometry of the effective molecule titrations of C3b and factor B, and the first-order kinetics displayed by the generation and decay of the factor B-dependent hemolytic site are characteristics consistent with the one-hit theory as initially developed for the classical complement system. The use of hemolytically active cellular intermediates to examine the reactions occurring with C3b and factors B and D has allowed extension of the one-hit theory to this molecular sequence, development of effective molecule titrations, recognition of the analogies to the functional characteristics of the classical C3 convertase, and discrimination of the probable mechanism of terminal complement activation from reactive lysis.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4202731      PMCID: PMC2139460          DOI: 10.1084/jem.138.6.1305

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Reaction mechanisms of nascent C567 (reactive lysis). I. Reaction characteristics for production of EC567 and lysis by C8 and C9.

Authors:  J N Goldman; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1972-08       Impact factor: 5.422

2.  A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

3.  Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

4.  Alterations in human serum beta-1C-gobulin (C'3) in renal transplantation.

Authors:  C B Carpenter; T J Gill; J P Merrill; G J Dammin
Journal:  Am J Med       Date:  1967-12       Impact factor: 4.965

5.  Functional relationship of factor B in the properdin system to C3 proactivator of human serum.

Authors:  I Goodkofsky; I H Lepow
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

6.  C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1969-03       Impact factor: 5.422

7.  Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation.

Authors:  L G Hunsicker; S Ruddy; C B Carpenter; P H Schur; J P Merrill; H J Müller-Eberhard; K F Austen
Journal:  N Engl J Med       Date:  1972-10-26       Impact factor: 91.245

8.  Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system.

Authors:  O Götze; H J Müller-Eberhard
Journal:  N Engl J Med       Date:  1972-01-27       Impact factor: 91.245

9.  Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.

Authors:  P J Lachmann; R A Thompson
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  63 in total

1.  Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.

Authors:  S Ruddy; K F Austen; E J Goetzl
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

2.  Electron spin resonance studies on interaction of complement proteins with erythrocyte membranes.

Authors:  C E Dahl; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

Review 3.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

4.  Deficiency of factor B of the complement system in sickle cell anaemia.

Authors:  W A Wilson; G R Hughes; P J Lachmann
Journal:  Br Med J       Date:  1976-02-14

5.  Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus.

Authors:  M D Kazatchkine; D T Fearon; M D Appay; C Mandet; J Bariety
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

6.  Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

Authors:  Sarah E Sartain; Nancy A Turner; Joel L Moake
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

7.  Isolation and characterization of rat complement factor B and its interaction with cell-bound human C3.

Authors:  M R Daha; L A van Es
Journal:  Immunology       Date:  1980-12       Impact factor: 7.397

8.  Studies on the inhibition of C56-initiated lysis (reactive lysis). V. The roleof C567-INH in the regulation of complement-dependent haemolysis initiated by cobravenom factor.

Authors:  B McLeod; T F Lint; P Baker; C Behrends; H Gewurz
Journal:  Immunology       Date:  1975-04       Impact factor: 7.397

9.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.

Authors:  A Nicholson-Weller; J P March; S I Rosenfeld; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

10.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.